|
- Chiesi USA
Chiesi USA is committed to developing and commercializing products that meet the needs of healthcare providers and their patients We deliver our products and associated services to improve the lives of patients
- About us - Chiesi USA
Chiesi is a sustainable pharmaceutical company committed to generating economic value in a way that also benefits society by addressing its needs and challenges, thus connecting the company’s success with social progress We are dedicated to people, patients, and the planet
- CHIESI USA, Inc.
Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment
- Products - Chiesi USA
Chiesi USA is committed to developing and commercializing products that meet the needs of healthcare providers and their patients We deliver our products and associated services to improve the treatment of patients
- Current Openings - Chiesi USA
We’re so glad you’re considering joining Chiesi USA, Inc (Chiesi [key-ay-zee]) At Chiesi, we’re proud to be a Public Benefit Corporation and a certified B Corp, following high standards for social and environmental impact
- History - Chiesi USA
Chiesi USA was established in 2014 with the acquisition of Cornerstone Therapeutics Inc , as the culmination of a strong strategic alliance first formed in 2009 The organizations shared a focus on their people and a desire to address unmet medical needs in the specialty setting
- CHIESI USA, Inc.
As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035
- Pipeline - Chiesi USA
Chiesi USA’s development pipeline consists of new molecular entities and continues to make significant progress Programs include innovative anti-inflammatory, bronchodilator, and antifibrotic molecules
|
|
|